---
title: "I-Mab Reports H1 2025 Financial Results Amid Strategic Shift"
description: "I-Mab (IMAB) reported its H1 2025 financial results on October 6, 2025, amid a strategic shift involving the divestiture of Greater China assets and internal restructuring to cut R&D expenses. This ch"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260044858.md"
published_at: "2025-10-06T11:28:52.000Z"
---

# I-Mab Reports H1 2025 Financial Results Amid Strategic Shift

> I-Mab (IMAB) reported its H1 2025 financial results on October 6, 2025, amid a strategic shift involving the divestiture of Greater China assets and internal restructuring to cut R&D expenses. This change may affect operations and market positioning. Analysts rate IMAB stock as a Buy with a $9.00 target, but Spark's AI Analyst gives it a Neutral score due to financial challenges, ongoing losses, and a negative P/E ratio. I-Mab focuses on developing biologics for unmet medical needs in immuno-oncology and autoimmune diseases.

The latest update is out from I-MAB ( (IMAB) ).

On October 6, 2025, I-Mab announced its financial results for the first half of 2025, highlighting unaudited condensed consolidated financial statements. The announcement is part of a strategic reprioritization, including the divestiture of its Greater China assets and internal restructuring, which is expected to reduce research and development expenses. This move is likely to impact the company’s operations and market positioning, potentially affecting stakeholders and future financial performance.

The most recent analyst rating on (IMAB) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.

**Spark’s Take on IMAB Stock**

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

**More about I-MAB**

I-Mab is a biopharmaceutical company focused on the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly in the areas of immuno-oncology and autoimmune diseases.

**Average Trading Volume:** 2,220,915

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $342.1M

For an in-depth examination of IMAB stock, go to TipRanks’ Overview page.

### Related Stocks

- [IMAB.US - I-Mab](https://longbridge.com/en/quote/IMAB.US.md)
- [NBP.US - NovaBridge Biosciences](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美團 (3690) 盈警，料去年度業績由盈轉虧 | 美團近日發出盈警，預計 2025 年度將錄得虧損 233 億至 243 億元人民幣，較 2024 年盈利 358 億元大幅惡化。虧損主要源於核心本地商業分部的經營虧損及對海外業務的加大投入。美團已加大對生態體系的投入以應對激烈競爭，包括強化 | [Link](https://longbridge.com/en/news/276027930.md) |
| TVB 與 ViuTV 經營策略歧異｜林小珍 | TVB 與 ViuTV 在經營策略上存在明顯差異。TVB 預計去年 EBITDA 超過 3.5 億元，整體業績將由虧轉盈，純利預計超過 5,000 萬元。然而，ViuTV 的 EBITDA 為 1.53 億元，同比下降 20%，但下半年已恢 | [Link](https://longbridge.com/en/news/275586331.md) |
| Barzolvolimab 為自發性蕁麻疹提供了長期的改善效果 | Barzolvolimab 在治療自發性蕁麻疹方面顯示出長期療效，在 2026 年 AAAAI 年會上展示的第二階段研究中觀察到了顯著改善。在 52 周的治療後，71% 的患者達到了完全緩解，且在治療後額外 28 周內持續受益。該研究表明可 | [Link](https://longbridge.com/en/news/275655959.md) |
| 威斯康星大學麥迪遜分校要求學生報告麻疹疫苗接種情況 | 威斯康星大學麥迪遜分校已要求學生披露其麻疹、腮腺炎和風疹等疾病的疫苗接種狀態，此舉是在校園內出現近期麻疹病例後實施的。該政策旨在增強公共健康意識，併為高風險學生提供更好的支持。此公告是在全國麻疹病例增加的背景下發布的，衞生官員呼籲進行疫苗接 | [Link](https://longbridge.com/en/news/275930065.md) |
| 在全球疼痛市場中，新機制和新模式存在顯著的機會 | 全球疼痛市場為創新提供了重大機會，特別是在開發非成癮性替代阿片類藥物方面。目前，全球批准的疼痛藥物中有 98% 是仿製藥，治療選擇缺乏多樣性。Vertex Pharmaceuticals 的 Journavx 最近獲得批准，標誌着一個突破， | [Link](https://longbridge.com/en/news/275921122.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.